Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Gene. 2019 Jul 20;706:131-139. doi: 10.1016/j.gene.2019.04.088. Epub 2019 May 2.
The high mobility group A2 (HMGA2; also called HMGI-C) gene is an architectural transcription factor that belonging to the high mobility group AT-hook (HMGA) gene family. HMGA2 is aberrantly regulated in several human tumors. Over-expression of HMGA2 is correlated with a higher risk of metastasis and an unfavorable prognosis in patients with cancer. We performed a meta-analysis to determine the clinic-pathological and prognostic value of HMGA2 overexpression in different human tumors. A comprehensive literature search was performed using PubMed, Embase, Cochrane Library, Scopus, MEDLINE, Google Scholar and ISI Web of Science. Hazard ratios (HRs)/odds ratios (ORs) and their 95% confidence intervals (CIs) were used to assess the strength of the association between HMGA2 expression and overall survival (OS)/progression free survival (PFS)/disease free survival (DFS). A total of 5319 patients with 19 different types of cancer from 35 articles were evaluated. Pooled data analysis indicated that increased HMGA2 expression in cancer patients predicted a poor OS (HR = 1.70; 95% CI = 1.6-1.81; P < 0.001; fixed-effect model). In subgroup analyses, high HMGA2 expression was particularly associated with poor OS in individuals with gastrointestinal (GI) cancer (HR = 1.89, 95% CI: 1.83-1.96; fixed-effect model) and HNSCC cancer (HR-1.78, 95%CI: 1.44-2.21; fixed-effect model). Over-expression of HMGA2 was associated with vascular invasion (OR = 0.16, 95% CI = 0.05-0.49; P = 0.001) and lymphatic invasion (OR = 1.89, 95% CI = 1.06-3.38; P = 0.032). Further studies should be conducted to validate the prognostic value of HMGA2 for patients with GI cancers.
高迁移率族 A2（HMGA2；也称为 HMGI-C）基因是一种结构转录因子，属于高迁移率族 AT 钩（HMGA）基因家族。HMGA2 在几种人类肿瘤中异常调节。HMGA2 的过表达与癌症患者转移风险增加和预后不良相关。我们进行了一项荟萃分析，以确定 HMGA2 在不同人类肿瘤中的过度表达的临床病理和预后价值。使用 PubMed、Embase、Cochrane 图书馆、Scopus、MEDLINE、Google Scholar 和 ISI Web of Science 进行了全面的文献检索。风险比（HRs）/优势比（ORs）及其 95%置信区间（CIs）用于评估 HMGA2 表达与总生存率（OS）/无进展生存率（PFS）/无病生存率（DFS）之间的关联强度。来自 35 篇文章的 5319 名患有 19 种不同类型癌症的患者进行了评估。汇总数据分析表明，癌症患者中 HMGA2 表达增加预示着 OS 不良（HR=1.70；95%CI=1.6-1.81；P<0.001；固定效应模型）。在亚组分析中，HMGA2 高表达与胃肠道（GI）癌症（HR=1.89，95%CI：1.83-1.96；固定效应模型）和头颈部癌症（HR-1.78，95%CI：1.44-2.21；固定效应模型）患者的 OS 不良特别相关。HMGA2 的过表达与血管侵犯（OR=0.16，95%CI=0.05-0.49；P=0.001）和淋巴侵犯（OR=1.89，95%CI=1.06-3.38；P=0.032）相关。应进一步开展研究，以验证 HMGA2 对 GI 癌症患者的预后价值。
